Bicara Therapeutics Inc. (BCAX)Healthcare | Biotechnology | Boston, United States | NasdaqGM
23.43 USD
-1.40
(-5.638%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 23.43 |
Hot Take ↕ | Aug. 22, 2026, 2:49 a.m. EDT
The investment case for Bicara Therapeutics is currently broken by a severe lack of financial viability and overwhelming market skepticism. Fundamentally, the company is burning cash with negative free cash flow and negative operating cash flow, while holding no dividend to offset capital deployment. The balance sheet, while showing low debt relative to equity, cannot sustain operations without external financing given the negative returns on assets and equity. The price action confirms this distress, trading well below its 52-week high and struggling to find support against the 200-day moving average. While the analyst consensus suggests a 'buy' based on potential future recovery, the data reveals a speculative vehicle with no earnings power. The options market reinforces this bearish sentiment, with traders aggressively buying insurance (puts) rather than betting on a rebound. This is a high-risk speculative play suitable only for investors willing to accept total loss potential in exchange for asymmetric upside on a clinical trial success, but it fails every standard metric of a sound investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.213450 |
| AutoTheta | 0.217911 |
| AutoETS | 0.218042 |
| AutoARIMA | 0.218278 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 10.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.248 |
| Market Cap | 1,550,431,872 |
| Forward P/E | -6.82 |
| Website | https://www.bicara.com |
As of Aug. 22, 2026, 2:49 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest at strikes near the current price ($22.50 and $25.00), while call activity remains sparse and concentrated far out-of-the-money. The implied volatility skew shows significantly higher premiums for downside protection compared to upside speculation, indicating a market consensus expecting continued weakness or a lack of catalyst-driven rallies in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0865545 |
| Address1 | 116 Huntington Avenue |
| Address2 | Suite 703 |
| All Time High | 30.99 |
| All Time Low | 7.8 |
| Ask | 32.75 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 492,510 |
| Average Daily Volume3 Month | 730,933 |
| Average Volume | 730,933 |
| Average Volume10Days | 492,510 |
| Bid | 18.74 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 7.11 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 23.43 |
| Current Ratio | 11.589 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 24.56 |
| Day Low | 23.36 |
| Debt To Equity | 0.248 |
| Display Name | Bicara Therapeutics |
| Earnings Call Timestamp End | 1,786,451,400 |
| Earnings Call Timestamp Start | 1,786,451,400 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,313,800 |
| Earnings Timestamp Start | 1,794,313,800 |
| Ebitda | -201,834,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.224 |
| Enterprise Value | 1,054,335,872 |
| Eps Current Year | -3.35643 |
| Eps Forward | -3.43615 |
| Eps Trailing Twelve Months | -2.9 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.5887 |
| Fifty Day Average Change | -3.158699 |
| Fifty Day Average Change Percent | -0.118798554 |
| Fifty Two Week Change Percent | 108.65546 |
| Fifty Two Week High | 30.99 |
| Fifty Two Week High Change | -7.5599995 |
| Fifty Two Week High Change Percent | -0.24394965 |
| Fifty Two Week Low | 10.295 |
| Fifty Two Week Low Change | 13.135 |
| Fifty Two Week Low Change Percent | 1.2758621 |
| Fifty Two Week Range | 10.295 - 30.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,234,200,000 |
| Float Shares | 36,900,013 |
| Forward Eps | -3.43615 |
| Forward P E | -6.818678 |
| Free Cashflow | -76,946,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 103 |
| Fullday Change | -1.4 |
| Fullday Change Percent | -5.63834 |
| Fullday Price | 23.43 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10067 |
| Held Percent Institutions | 1.07708 |
| Implied Shares Outstanding | 66,172,934 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-09-13 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. |
| Long Name | Bicara Therapeutics Inc. |
| Market | us_market |
| Market Cap | 1,550,431,872 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_674698236 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -185,363,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,642,412,221 |
| Number Of Analyst Opinions | 14 |
| Open | 24.56 |
| Operating Cashflow | -134,848,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 468 4219 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 23.43 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 24.83 |
| Price Eps Current Year | -6.9806314 |
| Price Hint | 2 |
| Price To Book | 3.2953587 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.438 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.5625 |
| Region | US |
| Regular Market Change | -1.4 |
| Regular Market Change Percent | -5.63834 |
| Regular Market Day High | 24.56 |
| Regular Market Day Low | 23.36 |
| Regular Market Day Range | 23.36 - 24.56 |
| Regular Market Open | 24.56 |
| Regular Market Previous Close | 24.83 |
| Regular Market Price | 23.43 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 524,734 |
| Return On Assets | -0.26142 |
| Return On Equity | -0.41011003 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 66,172,934 |
| Shares Percent Shares Out | 0.15810001 |
| Shares Short | 10,463,188 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,315,906 |
| Short Name | Bicara Therapeutics Inc. |
| Short Percent Of Float | 0.2202 |
| Short Ratio | 17.09 |
| Source Interval | 15 |
| State | MA |
| Symbol | BCAX |
| Target High Price | 45.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 33.5 |
| Target Median Price | 34.5 |
| Total Cash | 497,259,008 |
| Total Cash Per Share | 7.515 |
| Total Debt | 1,163,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.749 |
| Two Hundred Day Average Change | 2.6809998 |
| Two Hundred Day Average Change Percent | 0.12921104 |
| Type Disp | Equity |
| Volume | 524,734 |
| Website | https://www.bicara.com |
| Zip | 2,116 |